Evidence map›Paper›PMID 33777193›Full record

ArticleExperimental and therapeutic medicine2021

microRNA-23 inhibits inflammation to alleviate rheumatoid arthritis via regulating CXCL12.

Bo Gao, Guomin Sun, Yan Wang, Yaqin Geng, Lei Zhou, Xi Chen

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bo GaoDepartment of Rheumatology and Immunology, The Second Changzhou People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213004, P.R. China.
Guomin SunDepartment of Rheumatology and Immunology, The Second Changzhou People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213004, P.R. China.
Yan WangDepartment of Rheumatology and Immunology, The Second Changzhou People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213004, P.R. China.
Yaqin GengDepartment of Rheumatology and Immunology, The Second Changzhou People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213004, P.R. China.
Lei ZhouDepartment of Rheumatology and Immunology, The Second Changzhou People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213004, P.R. China.
Xi ChenDepartment of Rheumatology and Immunology, The Second Changzhou People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213004, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a common systemic, inflammatory and autoimmune disorder. MicroRNAs (miRs) are strongly associated with the initiation and progression of RA. However, the functions and mechanisms underlying miR-23 in RA are not completely understood. Therefore, the present study aimed to investigate the molecular mechanisms underlying miR-23 in RA. A bioinformatics tool (StarBase) and a wide range of experimental assays, including reverse transcription-quantitative PCR, western blotting, luciferase reporter assays and ELISAs, were performed to investigate the biological role of miR-23 in RA. The results indicated that miR-23 was downregulated and chemokine C-X-C motif ligand 12 (CXCL12) was upregulated in RA samples compared with healthy samples. Furthermore, miR-23 overexpression suppressed inflammation via reducing TNF-α, IL-1β and IL-8 expression levels compared with the NC mimic group. Regarding the underlying mechanism, compared with NC mimic, miR-23 mimic decreased CXCL12 mRNA expression by binding to its 3'-untranslated region. Additionally, CXCL12 overexpression reversed miR-23 mimic-mediated effects on inflammation. NF-κB signaling is associated with inflammation. Therefore, the present study indicated that CXCL12 promoted inflammation by activating NF-κB signaling. In conclusion, miR-23 inhibited inflammation to alleviate RA by regulating CXCL12 via the NF-κB signaling pathway, which may serve as a potential target for the diagnosis and treatment of RA.

Indexed as

chemokine C-X-C motif ligand 12microRNA-23NF-κB signalingrheumatoid arthritis

Identifiers

PMID33777193
PMCPMC7967800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.